Nosis Bio Head of Research to speak at 2nd Annual Non-viral Delivery Conference

We are excited to announce that Chad Miller, Co-Founder and Head of Research at Nosis Biosciences, will be speaking at this year’s conference on RNA therapeutics, presenting a session titled, Hitting the Bullseye: Increasing Cell Specificity of Non-Viral Delivery Systems for Targeted Delivery of RNA. In this highly anticipated talk, Chad will share groundbreaking insights into how Nosis Bio is advancing RNA delivery methods to achieve unprecedented cell specific delivery to extrahepatic tissues.

RNA therapeutics hold immense potential, but their efficacy hinges on the ability to deliver RNA molecules precisely to target cells. Chad’s session will cover how Nosis Bio is developing non-viral, cell-targeting delivery vehicles designed to maximize therapeutic impact while minimizing off-target effects. Key topics of the presentation include:

• The Therapeutic Opportunity of Cell-Specific RNA Delivery: Chad will explore the vast potential that cell-specific RNA delivery unlocks for treating a range of diseases, particularly those rooted in specific cell types or tissues.

• Data from Internal Programs: Attendees will gain a firsthand look at the latest data from Nosis Bio’s RNA delivery programs, underscoring the efficacy of cell-targeting vehicles.

• A Novel Platform for Next-Generation Cell Targeting: Chad will introduce Nosis Bio’s proprietary platform for developing next-generation cell targeting vehicles, offering a detailed framework to inform other organizations working on similar delivery solutions.

This session promises to be invaluable for those in the field of RNA therapeutics, drug delivery, and biotech innovation. Attendees will leave with a deeper understanding of the strategies, technologies, and data driving Nosis Bio’s cutting-edge approach to cell-specific RNA delivery.

Join Chad and Nosis Biosciences in this journey towards more precise, effective RNA therapies.

‍